Applied DNA Biotherapeutics Subsidiary Reports LinearDNA Platform Development Milestone: First Successful Administration Of LinearDNA In Vivo Via Lipid Nanoparticles (LNP)
Applied DNA Biotherapeutics Subsidiary Reports LinearDNA Platform Development Milestone: First Successful Administration Of LinearDNA In Vivo Via Lipid Nanoparticles (LNP)
Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that LineaRx, the Company's majority-owned biotherapeutics subsidiary, has for the first time successfully administered and expressed a linearDNA-LNP construct in mice via routine intramuscular (IM) injection without the concurrent use of electroporation (EP) that utilizes electrical pulses to deliver DNA to target cells. The Company believes that the removal of the concurrent use of EP during administration potentially increases the commercial viability of LinearDNA-based therapies.
基于聚合酶链式反应的DNA技术领域的领先供应商应用DNA科学公司(纳斯达克股票代码：APDN)(以下简称“公司”)今天宣布，公司控股的生物治疗子公司LineaRx首次成功地通过常规肌肉注射(IM)在小鼠体内注射并表达了线性DNA-LNP结构，而无需同时使用利用电脉冲将DNA输送到靶细胞的电穿孔(EP)。该公司认为，在给药期间取消同时使用EP可能会增加基于LinearDNA的疗法的商业可行性。